Image

TELESCOPE- TELEhealth Shared Decision-making COaching

TELESCOPE- TELEhealth Shared Decision-making COaching

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

Hypothesis 1a: The investigators anticipate that navigator decision coaching, compared to enhanced usual care (EUC) will result in higher quality SDM for lung cancer screening (LCS )(primary outcome), greater knowledge of lung cancer screening benefits and harms, and lower decisional conflict.

Hypothesis 1b: Compared to enhanced usual care (EUC), we expect that TELESCOPE will result in more screening discussions, increased initial for lung cancer screening (LCS) with low-dose CT scan (LDCT) uptake among interested participants, increased adherence to repeat LCS and diagnostic testing, and increased smoking cessation referrals for current smokers.

Hypothesis 2: The investigators expect that a "booster" coaching session will increase adherence to repeat lung cancer screening (LCS).

Description

The investigators' primary objective is to compare the effectiveness of the TELESCOPE intervention vs. enhanced usual care (EUC) on shared decision-making (SDM) for lung cancer screening.

Secondary objectives are to test the effectiveness of the TELESCOPE intervention vs. EUC on screening uptake, adherence with diagnostic testing and annual testing, and smoking cessation referrals and receipt of tobacco treatment for current smokers. The investigators will also use a mixed methods approach to evaluate the implementation potential of navigator-led decision coaching for lung cancer screening (LCS ) and identify components and organizational and individual level characteristics that might facilitate or interfere with successful implementation.

Eligibility

Inclusion Criteria:

  • Inclusion Criteria Cluster Randomized Trial (N=420)
        Eligibility of patients for the cluster randomized trial will follow United States
        Preventive Services Task Force criteria for lung cancer screening. Specifically, patients
        must:
          -  Be 50 to 77 years of age
          -  Be a current or former smoker having quit within the past 15 years
          -  Have at least a 20 pack-year smoking history
          -  Be scheduled for a non-acute care visit at one of the study sites. Interviews (N=50)
        Participants completing the semi-structured interviews will be:
          -  A practicing primary care clinician or a clinic director (n=20), nursing director, or
             clinic practice administrator (n=20) at one of the participating sites or a TELESCOPE
             study patient navigator (n=7) and nurse navigator (n = 3)
          -  Age 18 or older
          -  Fluent in English Online surveys (N=130)
        Providers completing online PRISM construct surveys will be:
          -  A practicing primary care provider at one of the participating sites or a TELESCOPE
             study navigator
          -  Age 18 or older
          -  Fluent in English
        Exclusion Criteria:
        - Cluster Randomized Trial (N=420)
        Excluded will be patients who:
          -  Do not speak English
          -  Have a history lung cancer
          -  Were screened for lung cancer within the past 12 months
          -  Have health conditions that make them poor candidates for curative treatment as
             determined by the primary care provider
          -  Are unable to provide informed consent Interviews (N=50)
        Providers/administrators will be excluded if they:
          -  Are unable to provide informed consent Online surveys (N=130)
          -  Are unable to provide informed consent
          -  Women who are pregnant. English proficiency is required for the completion of surveys,
             and the intervention will be conducted in English.

Study details
    Lung Neoplasms

NCT05491213

Rutgers, The State University of New Jersey

10 June 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.